Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $72.00 target price on the biopharmaceutical company’s stock. JMP Securities’ target price would indicate a potential upside […]
Related Keywords
Ireland , Belgium , Japan , United States , Switzerland , Michaelj Labarre , , Halozyme Therapeutics Inc , Bessemer Group Inc , Covestor Ltd , Halozyme Therapeutics Company Profile , Montaga Associates Inc , Tower Group , Massmutual Trust Co , Morgan Stanley , Halozyme Therapeutics , Get Free Report , Halozyme Therapeutics Daily , Nasdaq Halo , Halo , Medical , 40637h10 , Reiterated Rating , Jmp Securities ,
vimarsana.com © 2020. All Rights Reserved.